The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women

Osteoporosis International

Volumn 16, Issue 11, 2005, Pages 1368-1374

  Mezquita Raya, Pedro ^a   De La Higuera, Magdalena ^a   García, Diego Fernández ^a   Alonso, Guillermo ^a   Ruiz Requena, María Estrella ^a   De Dios Luna, Juan ^b   Escobar Jiménez, Fernando ^a   Muñoz Torres, Manuel ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Bone mineral density; Osteoprotegerin; Postmenopausal osteoporosis; RANK L; Vertebral fracture

Indexed keywords

ESTRADIOL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ABSORPTIOMETRY; ADULT; AGE DISTRIBUTION; AGED; ANTHROPOMETRY; ARTICLE; BONE MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; VERTEBRA FRACTURE;

ACID PHOSPHATASE; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; CARRIER PROTEINS; DENSITOMETRY, X-RAY; ESTRADIOL; FEMALE; FEMUR NECK; GLYCOPROTEINS; HUMANS; ISOENZYMES; LUMBAR VERTEBRAE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SPINAL FRACTURES;

EID: 27444445921     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1844-1     Document Type: Article

References (29)

1. Hofbauer LC, Khosla S, Dunstan CR, Lacey D, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
2. Yasuda H, Shima N, Nakagawa N et al (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337
3. Akatsu T, Murakami T, Ono K et al (1998) Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23:495-498
4. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
5. Bekker PJ, Holoway DL, Rasmussen AS, et al (2004) A single-dose placebo-controlled study of AMG 162, fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370
7. Schevde NK, Bendixen A, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 977:829-834
8. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
9. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230
10. Yano K, Tsuda E, Washida N et al (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. J Bone Miner Res 14:518-527
11. Khosla S, Arrighi HM, Melton III LJ et al (2002) Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399
12. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
13. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R (2002) Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475
14. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2004) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32:681-686
15. Schett G, Stefan K, Redlich K et al (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291:1108-1113
16. Pennisi P, Signorelli SS, Riccobene S et al (2004) Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15:389-395
17. Rinaldi S, Déchaud H, Biessy C et al (2001) Reliability and validity of commerciallyavailable, direct radioimmunoassays for measurements of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomark Prev 10:757-765
18. Diaz Curiel M, Carrasco de la Peña JL, Honorato Perez J, Perez Cano R, Rapado A, Ruiz Martinez I (1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre Research Project on Osteoporosis. Osteoporos Int 7:59-64
19. Orwoll ES, Oviatt SK, Mann T (1990) The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. J Clin Endocrinol Metab 70:1202-1207
20. Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843:1-129
21. Cook GJ, Lodge MA, Blake GM, Marsden PK, Fogelman I (2000) Differences in skeletal kinetics between vertebral and humeral bone measured by 18Ffluoride positron emission tomography in postmenopausal women. J Bone Miner Res 15:763-769
22. Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A (2003) Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 88:5361-5365
23. Hegedus D, Ferencz V, Lakatos PL et al (2002) Decreased bone density, elevated serum osteoprotegerin, and b-cross-laps in Wilson disease. J Bone Miner Res 17:1961-1967
24. Szalay F, Hegedus D, Lakatos PL et al (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 38:395-400
25. Hofbauer LC, Schoppet M, Schüller P, Viereck V, Michael Christ M (2004) Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 60:14-219
26. Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32:136-141
27. Seck T, Diel I, Bismar H, Ziegler R, Pfeilschifter J (2001) Serum parathyroid hormone, but no menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 145:199-205
28. Riggs BL, Sundeep K, Melton LJ III (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302
29. Looker AC, Bauer DC, Chesnut CH III, et al (2000) Clinical use of biochemical markers of bone remodelling: current status and future directions. Osteoporosis Int 11:467-480